2-(3-methylbut-2-enyl)indan-1,3-dione | 1040247-65-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2-(3-methylbut-2-enyl)indan-1,3-dione
• CAS: 1040247-65-1
• 化学式: C₁₄H₁₄O₂
• 分子量: 214.264
• InChiKey: JNPICXFJULRNIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.04
• 重原子数：
  16.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  34.14
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  2-(3-methylbut-2-enyl)indan-1,3-dione 在 碘 作用下， 以 neat (no solvent) 为溶剂， 反应 24.0h， 以82%的产率得到2,2-dimethyl-3,4-dihydro-2H-indeno[1,2-b]pyran-5-one
  参考文献：
  名称：

  取代呋喃和吡喃的碘催化合成：反应范围和机理见解

  摘要：

  取代的吡喃和呋喃是广泛存在于各种天然产物和生物活性化合物中的核心结构。在此，我们报告了一种使用分子碘（一种简单且廉价的催化剂）合成取代吡喃和呋喃的实用且温和的催化方法。所描述的方法是在环境温度和气氛下在无溶剂条件下进行的，因此为当前可用的反应方案提供了一种简便实用的替代方案。实验研究和密度泛函理论计算的结合揭示了对这种看似简单的反应的有趣的机械见解。

  DOI：

  10.1021/acs.joc.1c00608
• 作为产物：
  描述：

  1,3-茚满二酮 、 1-溴-3-甲基-2-丁烯 在 potassium carbonate 作用下， 以 氯仿 为溶剂， 反应 18.0h， 以16%的产率得到2-(3-methylbut-2-enyl)indan-1,3-dione
  参考文献：
  名称：

  Synthetic methods for the preparation of ARQ 501 (β-Lapachone) human blood metabolites

  摘要：

  ARQ 501 (3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione), a synthetic version of beta-Lapachone, is a promising anti-cancer agent currently in multiple Phase II clinical trials. Promising anti-cancer activity was observed in Phase I and Phase II trials. Metabolism by red blood cells of drugs is an understudied area of research and the metabolites arising from oxidative ring opening (M2 and M3), decarbonylation/ ring contraction (M5), and decarbonylation/ oxidation (M4 and M6) of ARQ 501 offer a unique opportunity to provide insight into these metabolic processes. Since these metabolites were not detected in in vitro incubations of ARQ 501 with liver microsomes and were structurally diverse, confirmation by chemical synthesis was considered essential. In this report, we disclose the synthetic routes employed and the characterization of the reference standards for these blood metabolites as well as additional postulated structures, which were not confirmed as metabolites. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.03.073

文献信息

• Iodine-Catalyzed Synthesis of Substituted Furans and Pyrans: Reaction Scope and Mechanistic Insights
  作者：Domenic P. Pace、Raphaël Robidas、Uyen P. N. Tran、Claude Y. Legault、Thanh Vinh Nguyen

  DOI：10.1021/acs.joc.1c00608

  日期：2021.6.18

  Substituted pyrans and furans are core structures found in a wide variety of natural products and biologically active compounds. Herein, we report a practical and mild catalytic method for the synthesis of substituted pyrans and furans using molecular iodine, a simple and inexpensive catalyst. The method described is performed under solvent-free conditions at an ambient temperature and atmosphere,

  取代的吡喃和呋喃是广泛存在于各种天然产物和生物活性化合物中的核心结构。在此，我们报告了一种使用分子碘（一种简单且廉价的催化剂）合成取代吡喃和呋喃的实用且温和的催化方法。所描述的方法是在环境温度和气氛下在无溶剂条件下进行的，因此为当前可用的反应方案提供了一种简便实用的替代方案。实验研究和密度泛函理论计算的结合揭示了对这种看似简单的反应的有趣的机械见解。
• Synthetic methods for the preparation of ARQ 501 (β-Lapachone) human blood metabolites
  作者：Rui-Yang Yang、Darin Kizer、Hui Wu、Erika Volckova、Xiu-Sheng Miao、Syed M. Ali、Manish Tandon、Ronald E. Savage、Thomas C.K. Chan、Mark A. Ashwell

  DOI：10.1016/j.bmc.2008.03.073

  日期：2008.5

  ARQ 501 (3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione), a synthetic version of beta-Lapachone, is a promising anti-cancer agent currently in multiple Phase II clinical trials. Promising anti-cancer activity was observed in Phase I and Phase II trials. Metabolism by red blood cells of drugs is an understudied area of research and the metabolites arising from oxidative ring opening (M2 and M3), decarbonylation/ ring contraction (M5), and decarbonylation/ oxidation (M4 and M6) of ARQ 501 offer a unique opportunity to provide insight into these metabolic processes. Since these metabolites were not detected in in vitro incubations of ARQ 501 with liver microsomes and were structurally diverse, confirmation by chemical synthesis was considered essential. In this report, we disclose the synthetic routes employed and the characterization of the reference standards for these blood metabolites as well as additional postulated structures, which were not confirmed as metabolites. (C) 2008 Elsevier Ltd. All rights reserved.